AP Biosciences, Inc. (APBio) is excited to announce the submission of a Phase I human clinical trial application for its bispecific antibody program, AP505, to the U.S. Food and Drug Administration (FDA). AP505 is an innovative cancer immunotherapy targeting solid tumors by combining a PD-L1 antibody with a recombinant protein that neutralizes VEGF, offering a new approach to cancer treatment.
AP505 is designed to target two crucial pathways in cancer treatment:
- Blocking PD-1/PD-L1 Interaction: AP505 inhibits the interaction between PD-1 and PD-L1, preventing the suppression of T cell activation and enabling the immune system to attack tumor cells more effectively.
- Neutralizing VEGF to Inhibit Angiogenesis: The recombinant protein component of AP505 neutralizes VEGF, which is essential for tumor blood vessel formation, thus reducing tumor growth and enhancing the overall effectiveness of cancer therapy.
This dual-action bispecific antibody aims to address unmet medical needs in the treatment of solid tumors, offering a more comprehensive approach to cancer immunotherapy. For detailed clinical trial information, please visit: https://clinicaltrials.gov/study/NCT05650385.
AP505 will undergo several stages of clinical development, starting with the the regulatory review of the Phase I clinical trial application by the healthcare authority as the US FDA:
- Phase I Clinical Trial: Upon approval, the Phase I trial will evaluate the safety, tolerability, and preliminary efficacy of AP505 in cancer patients. The trial is expected to be completed by the end of 2024.
- Future Clinical Trials and Regulatory Reviews: Future trials be conducted based on the outcome received from the Phase I clinical trial. The following trials will further assess efficacy, dosage, and long-term safety, leading to the submission of marketing authorization application if applicable.
APBio is committed to advancing AP505 into the clinical trial phase. With Phase I expected to be completed by end-2024, the company will continue to evaluate its therapeutic potential and explore future licensing opportunities.
Cautionary Statements
New drug development requires a long process, vast investments and with no guarantee of success which may pose investment risks. The investors are advised to exercise caution and conduct a thorough evaluation.
